NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases. The presentation will take place…
NKGen Biotech, Inc. SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen,…
In the first instalment of a series to mark the 10th anniversary of the Future Science Prize, Holly Chik and Shen Xinmei look at Professor Dennis Lo’s groundbreaking discovery of fetal DNA in maternal plasma, which earned him the inaugural award in the Life Sciences category in 2016. The blood tests of the future can…
With ageing, neurodegenerative diseases like Alzheimer’s, Parkinson’s, and other types of dementia are one of the biggest threats to brain health. There is a genetic component to these diseases, but further research has shown that lifestyle can have a powerful influence on brain health. We spoke to Dr Avinash Kulkarni, Consultant Neurologist, Gleneagles BGS Hospital, Kengeri,…